Dermatology 2017-08-07T18:23:59+00:00


Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed.


Click the links below to download report overviews

Reports new KS-01

Quarterly survey of high dynamic markets, tracking brand usage, awareness, industry contacts and evolving perceptions.

RealTime Dynamix: Atopic Dermatitis US 2017 (quarterly)
RealTime Dynamix: Psoriasis US 2017 (quarterly)

Reports new KS-02

In-depth analysis of a robust sample of patient journeys detailing the realities of current practice.

RealWorld Dynamix: Biologic/Otezla Switching in Psoriasis US 2017